PainReform (NASDAQ:PRFX) Trading 1.3% Higher – What’s Next?

PainReform Ltd. (NASDAQ:PRFX)’s stock price shot up 1.3% during mid-day trading on Monday . The stock traded as high as $1.01 and last traded at $1.01. Approximately 49,309 shares traded hands during trading, a decline of 89% from the average daily volume of 438,878 shares. The stock had previously closed at $0.9971.

Analysts Set New Price Targets

A number of brokerages have recently commented on PRFX. Wall Street Zen raised shares of PainReform to a “sell” rating in a research report on Saturday, August 1st. Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a research note on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

PainReform Stock Down 2.0%

The firm has a 50-day moving average of $1.22 and a 200 day moving average of $1.93. The stock has a market capitalization of $848,250.00, a P/E ratio of -0.00 and a beta of 1.06.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.